CAS 336801-86-6
:Vapaliximab
Description:
Vapaliximab, with the CAS number 336801-86-6, is a monoclonal antibody designed for therapeutic applications, particularly in the treatment of autoimmune diseases. It functions by targeting specific immune pathways, thereby modulating the immune response. This compound is characterized by its high specificity and affinity for its target antigen, which is crucial for its efficacy and safety profile. Vapaliximab is typically administered via injection, and its pharmacokinetics involve a prolonged half-life, allowing for less frequent dosing compared to traditional therapies. The development of Vapaliximab is part of a broader trend in biopharmaceuticals, focusing on precision medicine and biologics that offer targeted treatment options with potentially fewer side effects. As with many monoclonal antibodies, its production involves complex biotechnological processes, including recombinant DNA technology. Ongoing clinical trials and studies are essential to fully understand its therapeutic potential, optimal dosing regimens, and long-term safety in various patient populations.
Formula:Unspecified
Synonyms:- Vapaliximab
- Immunoglobulin G2, anti-(human vascular adhesion protein VAP-1) (human-mouse monoclonal 2D10 γ2-chain), disulfide with human-mouse monoclonal 2D10 κ-chain, dimer
Sort by
The purity filter is not visible because current products do not have associated purity data for filtering.
Found 2 products.
Vapaliximab
CAS:Vapaliximab (2D10) is a monoclonal antibody against human VAP-1 [1] .
Color and Shape:Liquid
